fig1

Figure 1. Spectrum of NAFLD progression from steatosis to fibrosis. The gold standard diagnostic tool for the whole spectrum is still, despite the limitations, the liver biopsy: (left) the available serum-based noninvasive biomarkers; and (right) the imaging-based alternatives. NAFLD: nonalcoholic fatty liver disease; MRI: magnetic resonance imaging; MRE: magnetic resonance elastography; BMI: body mass index; FLI: fatty liver index; IR: insulin resistance; CK-18: cytokeratin 18; FGF21: fibroblast growth factor 21; PAI-1: plasminogen activator inhibitor-1; IL-1: interleukin 1; IL-8: interleukin 8; MCP-1: monocyte chemoattractant protein-1; FIB-4: the fibrosis-4 index